What Is the Normal Range for Pulmonary Artery Pressure?

In a healthy adult at rest, mean pulmonary artery pressure (mPAP) rarely exceeds 20 mmHg, and systolic pulmonary artery pressure typically falls between about 17 and 25 mmHg when measured directly by catheter. Those numbers sound reassuringly narrow, but the “normal” range shifts with age, body position, physical effort, altitude, and even time of day, which makes a single cutoff less tidy than it first appears. Understanding where normal ends and disease begins has itself been a moving target, with international guidelines recently lowering the threshold for pulmonary hypertension.

How Pulmonary Artery Pressure Is Measured

The gold-standard measurement comes from right heart catheterization, a procedure in which a thin, flexible catheter is threaded through a large vein and advanced into the pulmonary artery. Along the way it records pressures in the right atrium, right ventricle, and pulmonary artery itself, and it can also estimate cardiac output and pulmonary vascular resistance.¹ Because the catheter sits directly in the blood vessel, the numbers it produces are considered definitive. A comprehensive workup usually includes mean PAP, systolic PAP, diastolic PAP, and the pulmonary artery wedge pressure, each of which tells clinicians something different about how blood moves through the lungs and heart.²

Most people never undergo catheterization, though. The far more common first-line tool is transthoracic echocardiography, an ultrasound of the heart. Echo estimates systolic pulmonary artery pressure by measuring the speed of a tiny backward jet of blood through the tricuspid valve. In healthy people, an estimated systolic pressure above 30 mmHg on echo is considered outside the normal range.³ The catch is that this method depends on detecting enough backward flow through the valve to get a clean signal, and that signal is not always present. When no adequate tricuspid regurgitation jet can be measured, the echo simply cannot estimate pulmonary pressure, and the absence of that signal does not necessarily mean pressure is normal.⁴ Echo also tends to overestimate or underestimate the true pressure compared with catheterization, so when the clinical suspicion for pulmonary hypertension is high, doctors usually confirm the diagnosis invasively.⁵

Where Normal Ends and Pulmonary Hypertension Begins

For years the formal definition of pulmonary hypertension was a mean PAP of 25 mmHg or higher at rest, measured by catheter.⁶ But population studies consistently showed that the upper limit of normal in healthy adults is around 20 mmHg, leaving a gap between 21 and 24 mmHg that was neither clearly normal nor high enough to qualify as disease.⁷ International guidelines have since adopted 20 mmHg as the hemodynamic threshold, acknowledging that people with pressures in that borderline zone already show reduced exercise capacity and an abnormal pulmonary vascular response during exertion.⁸ In practical terms, a resting mean PAP of 21 to 24 mmHg should not be dismissed as “just borderline.” Systematic review data suggest that people in this range face a meaningfully higher risk of progressing to overt pulmonary hypertension and of dying compared with those whose pressures sit comfortably below 20.⁷

How Age, Sex, and Exercise Shift the Numbers

At rest, pulmonary artery pressure is remarkably stable across decades of life. A large systematic review found that resting mean PAP rarely exceeds 20 mmHg regardless of whether you are 25 or 65.⁹ Exercise is where age starts to matter. During mild exertion, people under 50 averaged a mean PAP of about 19 mmHg, while those 50 and older averaged roughly 29 mmHg, a difference large enough that values commonly exceed 30 mmHg in older individuals during physical activity.⁹ That age-related rise makes it difficult to define a single “normal” exercise pressure the way we can for resting pressure.

Sex also plays a role, at least earlier in life. In people under 45, men tend to have a mean PAP roughly 5 mmHg higher than women after adjusting for body size and race.¹⁰ After about age 45, the gap between the sexes narrows and largely disappears.¹⁰ The practical lesson is that a resting mean PAP of, say, 18 mmHg in a 30-year-old woman might be unremarkable, while the same number in a 30-year-old man sits closer to the population average for his group.

Posture, Time of Day, and Everyday Fluctuations

Pulmonary artery pressure is not a single fixed number throughout the day. Body position alone can swing it substantially. In heart failure patients fitted with implantable pressure sensors, switching from standing to lying down raised systolic PAP by an average of about 10 mmHg and mean PAP by roughly 7 mmHg.¹¹ Systemic blood pressure barely budged during the same posture change, so this is a phenomenon specific to the pulmonary circuit. Similar postural shifts have been documented in earlier ambulatory catheter studies, where lying down added roughly 9 mmHg to systolic PAP and about 6 mmHg to diastolic PAP.¹²

Nighttime pressures tend to be higher than daytime pressures as well, partly because people are lying down but not entirely for that reason. In the same ambulatory monitoring work, most patients showed a nocturnal rise of about 5 mmHg systolic and nearly 4 mmHg diastolic beyond what posture alone would explain.¹² For anyone interpreting a single pressure reading, the takeaway is straightforward: the conditions under which the measurement was taken, whether the person was supine or upright, whether it was morning or evening, matter more than many people assume.

Pulmonary Pressure in Newborns

Newborns are an exception to nearly every adult reference range. In the womb, pulmonary artery pressure is high because the lungs are filled with fluid and very little blood needs to flow through them. At birth, as the baby takes its first breaths and blood oxygen rises, pulmonary pressure and resistance drop sharply.¹³ The steepest decline happens in the first 24 hours. After that the fall is more gradual, and by two weeks of age, 95 percent of healthy full-term newborns have a systolic PAP below about 39 mmHg.¹⁴ That 39 mmHg ceiling would be flagged as elevated in an adult, which is why neonatal and adult reference ranges should never be mixed up. Premature infants may take even longer to reach adult-like pressures, and persistent pulmonary hypertension of the newborn is a well-recognized condition in which the normal postnatal drop fails to occur.

Why Pregnancy Does Not Raise Pulmonary Pressure the Way You Might Expect

Blood volume expands significantly during pregnancy, and the amount of blood flowing through the lungs increases by roughly 30 percent in the second trimester and up to about 45 percent by the third.¹⁵ You might expect pulmonary artery pressure to climb in step, but in healthy pregnancies it stays roughly unchanged. The reason is that pulmonary vascular resistance drops early in gestation, by around 13 to 17 percent, enough to absorb the extra flow without a meaningful rise in pressure.¹⁵ Both the increased flow and the decreased resistance tend to return to baseline within weeks after delivery. For women who already have borderline or elevated pulmonary pressures before conception, pregnancy can overwhelm this compensatory mechanism, which is one reason that pre-existing pulmonary hypertension is treated as a high-risk condition during pregnancy.

How Altitude Pushes Pulmonary Pressure Up

At high altitude the air contains less oxygen, and the pulmonary arteries respond by constricting, a reflex called hypoxic pulmonary vasoconstriction. The strength of this reflex varies enormously between people, likely on a genetic basis.¹⁶ In most lowlanders ascending to high altitude, pulmonary artery pressure rises modestly and returns to normal on descent. But in some individuals the response is exaggerated, contributing to high-altitude pulmonary edema, a potentially life-threatening condition in which fluid leaks into the lungs.¹⁷

Chronic exposure is a different story. People living for years at extreme altitude can develop structural remodeling of the small pulmonary arteries, leading to sustained pulmonary hypertension that overloads the right side of the heart.¹⁷ Populations native to high-altitude environments, such as Andean highlanders, show varying degrees of adaptation, but chronic mountain sickness with right heart failure has been documented in long-term residents and in soldiers stationed at extreme elevations.¹⁶ For a clinician evaluating pulmonary artery pressure, knowing the altitude at which a patient lives can change whether a given reading is interpreted as normal or abnormal.

What Causes Pulmonary Pressure to Stay Elevated

The World Health Organization sorts pulmonary hypertension into five categories based on the underlying mechanism.⁶ The most talked-about form, pulmonary arterial hypertension (PAH), involves narrowing and stiffening of the small pulmonary arteries themselves, restricting blood flow and driving up pressure.¹⁸ But PAH is actually uncommon. The most frequent cause of elevated pulmonary pressure is left-sided heart disease, where back-pressure from a failing or stiff left ventricle pushes fluid upstream into the lungs. Chronic lung diseases and blood clots that lodge in the pulmonary arteries are the other major drivers.¹⁹ Correctly identifying the category is critical because treatments designed for one type can be harmful if applied to another.¹⁸

Regardless of the cause, when pulmonary artery pressure stays elevated chronically, the right ventricle of the heart thickens in an attempt to keep pumping against the extra resistance. That adaptation can maintain cardiac output for a while, but right ventricular hypertrophy is rarely fully compensatory and may itself create ischemia within the heart muscle.²⁰ Once that compensatory wall-thickening reaches its limit, the right ventricle begins to fail, leading to fluid retention, reduced exercise tolerance, and ultimately right heart failure.²¹

Why Even Mild Elevations Matter for Prognosis

A landmark study of over a thousand patients who underwent catheterization found that mean PAP was the single strongest independent predictor of mortality, outperforming the number of blocked coronary arteries and left ventricular function. A 10 mmHg increase in mean PAP was associated with more than a fourfold increase in the risk of death, and this held true whether the patient’s left ventricle was pumping normally or not.²² That finding underscores why the shift to a 20 mmHg threshold matters: even modest elevations carry prognostic weight.

For people already diagnosed with pulmonary arterial hypertension, how pressure responds to exercise offers additional prognostic information. Patients whose systolic PAP rises robustly during exertion and who maintain a good cardiac output during exercise tend to survive longer than those whose hemodynamics stagnate or worsen with effort.²³ This is one reason that exercise testing during catheterization, though not routine everywhere, has gained traction as a way to refine risk assessment and guide treatment decisions. Current diagnostic guidelines recommend a stepwise approach that includes referral to a specialized center and invasive hemodynamic assessment whenever there is high suspicion for severe pulmonary vascular disease.²⁴

Current Treatments and Therapeutic Pathways

For pulmonary arterial hypertension specifically, the approved drug therapies target three biological pathways that go awry in the diseased pulmonary vessels: the nitric oxide pathway, the endothelin pathway, and the prostacyclin pathway.²⁵ In simplified terms, nitric oxide normally relaxes blood vessels, endothelin constricts them, and prostacyclin both dilates vessels and inhibits clotting. Drugs in these three classes work by restoring the balance between vessel relaxation and constriction. Over the past three decades, medications addressing these pathways have significantly improved exercise capacity and survival in PAH, though the disease remains incurable.²⁶ Combination therapy, using drugs from two or even all three pathways simultaneously, has become standard in many patients with more advanced disease.

For the more common forms of pulmonary hypertension driven by left heart disease or chronic lung conditions, PAH-specific medications are generally not used because addressing the underlying cause is what lowers the pressure. Treating the heart failure, managing the lung disease, or removing blood clots in the case of chronic thromboembolic disease are the primary strategies.

Implantable Sensors and Continuous Monitoring

One of the more interesting developments in the field is the ability to track pulmonary artery pressure continuously without repeated catheterizations. A small wireless sensor implanted in a branch of the pulmonary artery can transmit daily pressure readings to a clinician’s dashboard.²⁷ The device was originally developed for heart failure management, where subtle rises in filling pressures often precede clinical worsening by days or weeks. The randomized CHAMPION trial tested whether adjusting treatment based on these daily readings could reduce hospitalizations compared with standard care.²⁸

More recently, the same technology has been explored in patients with pulmonary arterial hypertension itself, extending its use beyond heart failure.²⁹ Continuous monitoring captures the kind of everyday variability discussed earlier, including postural swings and nocturnal rises, and lets clinicians spot upward trends before symptoms appear. It also reinforces a point that applies to anyone trying to understand their own pulmonary artery pressure: a single snapshot reading, taken under controlled conditions on one particular morning, only tells part of the story.

How Pulmonary Vascular Responses Vary Across Species

Humans are not the only animals with variable pulmonary vascular tone, and comparing species sheds light on why some people handle elevated pressures better than others. In experiments comparing dogs, goats, and pigs, the baseline tone and hypoxic reactivity of the pulmonary vessels differed markedly. Pigs showed the strongest vasoconstrictor response and the most dramatic rise in pulmonary pressure during hypoxia, while dogs showed the least.³⁰ These differences reflect both the structure of the pulmonary arteries and how the right ventricle adapts to sudden pressure increases. In species with naturally high pulmonary vascular reactivity, the right ventricle appears less able to compensate, a pattern that may echo the wide range of human responses to hypoxia at high altitude. The variability in human hypoxic pulmonary vasoconstriction, the same trait that determines who gets altitude sickness, likely has a similar genetic and structural basis.